Pyramax® edges closer to patients

New MMV-sponsored antimalarial receives approval from the Korean FDA.
19 August 2011

Pyramax (pyronaridine-artesunate), a new fixed-dose artemisinin combination therapy (ACT) has received approval from the Korean Food and Drug Administration (KFDA) on 17 August 2011. The ACT was developed by Shin Poong Pharmaceuticals of Korea in partnership with MMV.

“Medicines for Malaria Venture is proud to be collaborating with one of Korea’s leading pharmaceutical companies, Shin Poong Pharmaceuticals, in the development of Pyramax,” said David Reddy, MMV’s CEO. “Shin Poong’s long-standing commitment to researching new drugs for neglected diseases made them a strong and reliable partner for MMV. Pyramax is an exciting new treatment for both uncomplicated P.falciparum malaria and P.vivax malaria. Its approval by the Korean FDA is the first step towards providing more choice to healthcare workers for the treatment of malaria and to help save more lives.”

The dossier is currently under review with the European Medicines Agency for approval under Article 58.